TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24325052
Drug: Thread-moxa in
Normalized name: Moxatag
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thread-moxa in Zhuang folk medicine combined with acupuncture and Jingwanhong Scald Ointment
Study: 24325052
Drug: Famciclovir Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir Tablet, nimesulide dispersible tablet, vitamin B1, ribavirin ointment (Control)
Study: 17487211
Drug: Plant sterol-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-enriched margarine (2.5 g/day)
Study: 17487211
Drug: Stanol-enriched margarine
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanol-enriched margarine (2.5 g/day)
Study: 17241586
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of bleomycin with electroporation (EP)
Study: 17241586
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of bleomycin alone
Study: 15229960
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 660 mg
Study: 15229960
Drug: Ibuprofen 1200
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1200 mg
Study: 15229960
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 440 mg (subgroup aged > or = 65 years)
Study: 15229960
Drug: Ibuprofen 1200
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1200 mg (subgroup aged > or = 65 years)
Study: 15229960
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 440/660 mg
Study: 11194534
Drug: Continuous gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous gastric infusion (CGI)
Study: 9113631
Drug: Dietary Arachidonic
Normalized name: arachidonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Arachidonic Acid (1.7 g/d for 50 days)
Study: 9113631
Drug: Control Diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Diet (210 mg/d of Arachidonic Acid)
Study: 8471596
Drug: Adoptive chemoimmunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive chemoimmunotherapy (ACIT) using autolymphocyte therapy (ALT) and cyclophosphamide
Study: 30921345
Drug: Two-day split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day split dose regimen
Study: 30921345
Drug: One-day split
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day split dose regimen
Study: 17684801
Drug: Atorvastatine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatine treatment for 21 days
Study: 17684801
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basis therapy only)
Study: 10204900
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg morphine diluted in 100 mL 0.9% normal saline (NS) and placebo intramuscular (i.m.) (peripheral MS group)
Study: 10204900
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 0.9% NS alone and placebo i.m. (placebo group)
Study: 10204900
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 0.9% NS and 6 mg morphine i.m. in the deltoid muscle (i.m. MS group)
Study: 8657439
Drug: Regional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional intravenous guanethidine blockade (RGB)
Study: 8657439
Drug: Placebo (tourniquet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tourniquet inflation and i.v. injection of saline)
Study: 2187006
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (1000 mg twice daily)
Study: 382151
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg orally t.d.s. before meals)
Study: 31913228
Drug: TX-001HR (17β-estradiol/progesterone)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TX-001HR (17β-estradiol/progesterone) at various doses (1/100, 0.5/100, 0.5/50, or 0.25/50)
Study: 30829213
Drug: Mukalbion poly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mukalbion poly herbal chewable tablets
Study: 25172115
Drug: Desmopressin (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (medication used to treat nocturia)
Study: 22809601
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10 mg/kg followed by 5 mg/kg at 24 hours and 48 hours)
Study: 22809601
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline at 1 mL/kg followed by 0.5 mL/kg at 24 hours and 48 hours)
Study: 19237683
Drug: Simplified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified treatment algorithm (initial therapy with low-dose ACE inhibitor/diuretic or ARB/diuretic combination, up-titration to highest dose, addition of calcium channel blocker, addition of non-first-line antihypertensive agent)
Study: 19237683
Drug: Simplified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified treatment algorithm
Study: 17573877
Drug: Ketoconazole 2%
Normalized name: KETOCONAZOLE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 2% cream without occlusion (group I)
Study: 17573877
Drug: Ketoconazole 2%
Normalized name: KETOCONAZOLE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 2% cream with occlusion (group II)
Study: 17573877
Drug: Oxiconazole 1%
Normalized name: OXICONAZOLE 1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiconazole 1% cream without occlusion (group III)
Study: 17573877
Drug: Oxiconazole 1%
Normalized name: OXICONAZOLE 1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiconazole 1% cream with occlusion (group IV)
Study: 17573877
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment approach
Study: 17573877
Drug: Surgical nail
Normalized name: FUNGI NAIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical nail avulsion with topical antifungal agents
Study: 15068402
Drug: Theophylline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (4 mg/kg/day for under 12 years, 3 mg/kg/day for over 12 years)
Study: 8541278
Drug: Fish-oil capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil capsules (2.7 g n‐3 polyunsaturated fatty acids/d)
Study: 8541278
Drug: Olive-oil capsules
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive-oil capsules (4 g/d)
Study: 611326
Drug: Astrand‐Ryhming Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astrand‐Ryhming Test administered at 50 rpm
Study: 611326
Drug: Astrand‐Ryhming Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astrand‐Ryhming Test administered at 80 rpm
Study: 21995388
Drug: MF59-adjuvant vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvant vaccine (ATIV)
Study: 21995388
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine without adjuvant (TIV)
Study: 21995388
Drug: Control (noninfluenza)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (noninfluenza) vaccines
Study: 15625793
Drug: Habituation-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habituation-based treatment (5 sessions)
Study: 11048414
Drug: Cefazolin administration
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administration (1 mg i.v. after ligation of the umbilical cord)
Study: 11048414
Drug: Cefazolin administration
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administration
Study: 2256055
Drug: l-selenium-methionine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-selenium-methionine (200 micrograms daily)
Study: 2256055
Drug: peaselenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: peaselenium (200 micrograms daily)
Study: 6170414
Drug: L-6 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-6 regimen (control)
Study: 6170414
Drug: L-12 protocol
Normalized name: L-cis-1,2-epoxypropylphosphonic acid
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-12 protocol
Study: 6170414
Drug: L-6 protocol
Normalized name: 6-ammonio-L-norleucine
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-6 protocol (control)
Study: 25426541
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (9.3 g of protein/566.4 KJ) plus exercise
Study: 23602843
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (ET) with dextranomer hyaluronic acid copolymer (Dx/HA)
Study: 21093286
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil dietary supplementation, 6 g/day (720 mg of DHA and 1,080 mg of EPA)
Study: 19436226
Drug: 0.25% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% DHEA (Prasterone) 1.3 mL ovules
Study: 19436226
Drug: 0.5% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% DHEA (Prasterone) 1.3 mL ovules
Study: 19436226
Drug: 1.0% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% DHEA (Prasterone) 1.3 mL ovules
Study: 15540634
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment (NDT) twice a week for 16 weeks
Study: 15540634
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment (NDT) five times a week for 16 weeks
Study: 9646600
Drug: Extended outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended outpatient treatment of 180 days
Study: 9646600
Drug: Regular outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular outpatient treatment of 90 days
Study: 20701567
Drug: Traditional Indigenous
Normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Indigenous Games (TIG) delivered weekly for three months
Study: 14656033
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid (5 mg/day)
Study: 8633144
Drug: 2 mL/sec
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL/sec
Study: 8633144
Drug: 3 mL/sec
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL/sec
Study: 8633144
Drug: 4.5 mL/sec
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mL/sec
Study: 8633144
Drug: 6 mL/sec
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL/sec
Study: 1424880
Drug: Formoterol suspension
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol suspension aerosol (12 micrograms, twice daily)
Study: 1424880
Drug: Formoterol solution
Normalized name: formoterol Inhalation Solution
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol solution aerosol (12 micrograms, twice daily)
Study: 2933119
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tetracycline and oestrogen‐cyproterone acetate
Study: 30527419
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate therapy
Study: 3096181
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sodium bicarbonate therapy)
Study: 21141077
Drug: Long-acting carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting carteolol hydrochloride 2% ophthalmic solution (LA), administered once a day
Study: 21141077
Drug: Original carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original carteolol hydrochloride 2% ophthalmic solution (CA), administered twice a day
Study: 17068328
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin on alternate days
Study: 16140593
Drug: Topiramate (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (200-400 mg/day for adults or 5-9 mg/kg/day for children)
Study: 12145765
Drug: Vehicle (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (300 mL water with noncaloric flavoring)
Study: 7638685
Drug: Very-low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-protein diet (0.4 g protein/kg/day supplemented with essential amino acids)
Study: 7638685
Drug: Conventional low-protein
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional low-protein diet (0.6 g protein/kg/day)
Study: 11994055
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C
Study: 576879
Drug: All Treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All Treatments
Study: 25722381
Drug: Trametinib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (2 mg orally once daily)
Study: 25722381
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 i.v. every 3 weeks)
Study: 21235774
Drug: Mobile Cognitive
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile Cognitive Therapy (M-CT) in addition to treatment as usual (TAU)
Study: 19586231
Drug: Day treatment,
Normalized name: Coartem 3-Day Treatment, 6 Tablet Blister Card
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment, abstinence-contingent housing, and vocational training (various combinations)
Study: 17584549
Drug: High-bolus-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-bolus-dose tirofiban (25 microg/kg over 3 minutes, followed by 0.15 microg/kg per minute for 18 to 24 hours)
Study: 7865492
Drug: CBS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS and metronidazole double therapy
Study: 7865492
Drug: CBS, metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS, metronidazole and amoxicillin triple therapy
Study: 81218
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy and cytoreductive surgery
Study: 30030134
Drug: Intervention (targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (targeted combination intervention)
Study: 22219060
Drug: Specific exercise
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific exercise program (9 exercises for lumbar region, executed daily for 8 minutes)
Study: 20737584
Drug: Dipyridamole (0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.56 mg/kg i.c.)
Study: 20737584
Drug: Verapamil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (1 mg i.c.)
Study: 18621929
Drug: Extracorporeal photopheresis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal photopheresis (ECP) and standard therapy
Study: 13679675
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (300 ml for two weeks)
Study: 13679675
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (300 ml for two weeks)
Study: 8777337
Drug: alpha interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha interferon therapy for 4 months
Study: 1836220
Drug: Fosinopril 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 5 mg, increased to 10 mg if DBP > 95 mmHg, administered orally once daily for 4 weeks
Study: 1836220
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg, increased to 50 mg if DBP > 95 mmHg, administered orally once daily for 4 weeks
Study: 6316670
Drug: Cefotaxime treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime treatment
Study: 25341673
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide injection (first injection)
Study: 25341673
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide injection (second injection)
Study: 25341673
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide injection (third injection)
Study: 25341673
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid and NaCl injections
Study: 18809799
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for PMR with coronary artery bypass graft
Study: 18809799
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for PMR
Study: 12392825
Drug: Acetylcysteine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (400 mg orally twice daily) and 0.45% saline intravenously
Study: 2179754
Drug: Ciclosporin (CS)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin (CS) 5‐8 mg/kg/24 h and warfarin
Study: 7152084
Drug: Aludrox tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aludrox tablets for the first 2 weeks
Study: 7152084
Drug: Aludrox tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aludrox tablets
Study: 30975121
Drug: Combined smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined smoking with the highest exposure dose
Study: 21328434
Drug: DTI titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTI titration protocol (argatroban or bivalirudin)
Study: 20554370
Drug: aceclofenac 100mg-drotaverine
Normalized name: aceclofenac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aceclofenac 100mg-drotaverine 80 mg b.i.d
Study: 16118805
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autologous stem cell support (HDC)
Study: 16118805
Drug: Intermediate-dose chemotherapy
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose chemotherapy (IDC)
Study: 11772910
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glyburide orally
Study: 10189518
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of nimodipine
Study: 10189518
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of nimodipine
Study: 2182437
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (including doxorubicin intensification with or without asparaginase)
Study: 2182437
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive chemotherapy
Study: 27424036
Drug: Prednisone 2.5-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 2.5-60 mg daily for 7 days
Study: 22500844
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg/day plus Calcium 1000 mg/day and Vitamin D 100000 IU/month for 6 months
Study: 18562162
Drug: HR-titrated beta-blocker
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HR-titrated beta-blocker dosing regimen
Study: 18562162
Drug: Fixed-dose beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose beta-blocker dosing regimen
Study: 17609401
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (administered every 14 days for 12 weeks)
Study: 2689986
Drug: F 1.8
Normalized name: Gelato APF 1.81 % Dental Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: F 1.8 formula (1.8 g protein/100 mL)
Study: 2689986
Drug: F 1.3
Normalized name: Kaochlor S-F 1.33 MEQ/ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: F 1.3 formula (1.3 g protein/100 mL)
Study: 19358498
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment at Tinghui (GB 2), Yifeng (TE 17), Hegu (LI 4), Xiaxi (GB 43), Zhongzhu (TE 3)
Study: 19358498
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group with intravenous 6% low molecule dextran 500 mL with ATP and coenzyme A, and oral Nimodipine, Gold Theragan
Study: 16935718
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT scans at 15 mA
Study: 16935718
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT scans (tube current < 15 mA) with edge-preserving smoothing filter
Study: 16935718
Drug: High-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CT scans (55 mA)
Study: 2897780
Drug: bevantolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: bevantolol (200 to 400 mg)
Study: 28110896
Drug: mepolizumab 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab 75 mg IV
Study: 28110896
Drug: mepolizumab 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab 75 mg IV and SC
Study: 24094008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no orthodontic treatment (n = 14)